Citenamide

Citenamide

SCHEMBL636661

NC(=O)C1c2ccccc2C=Cc2ccccc21

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.57
LMNA P02545 3/20 0.47
HTR2A P28223 2/20 0.47
ALDH1A1 P00352 3/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 2/20 0.44
MAPK1 P28482 1/20 0.44
SCN4A P35499 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
KDM4E B2RXH2 3/20 0.42
POLB P06746 2/20 0.42
CYP2D6 P10635 2/20 0.40
CYP3A4 P08684 3/20 0.35
HSD17B10 Q99714 3/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 2/20 0.35
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citenamide SCHEMBL29446009 1.00 ATM (0.57) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL22418385 0.88 ATM (0.46) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL25220570 0.87 ATM (0.44) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL11710445 0.87 ATM (0.44) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL8797292 0.80 HTR2A (0.43) ATMLMNAHTR2AALDH1A1TSHR
SCHEMBL13955533 0.79 ATM (0.38) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL12143285 0.78 HTR2A (0.47) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL3143561 0.77 ATM (0.61) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL30250175 0.77 ATM (0.61) ATMLMNAHTR2AALDH1A1GAA
SCHEMBL6918423 0.76 ATM (0.46) ATMLMNAALDH1A1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-2672958-A1 COMPOSITION AND LIPID FORMULATION OF A HYALURONAN-DEGRADING ENZYME AND THE USE THEREOF FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Halozyme, Inc. (US) 2013-12-18 EP claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
WO-2012109387-A1 COMPOSITION AND LIPID FORMULATION OF A HYALURONAN-DEGRADING ENZYME AND THE USE THEREOF FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA HALOZYME, INC. (US) 2012-08-16 WO claimed
US-7939104-B2 Granulation; compaction; rapid dissolution upon contact with physiological solvents such as water, saliva or gastrointestinal fluids SANDOZ AG (CH) 2011-05-10 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-7607596-B1 Process for enhancing the solubility of poorly soluble drugs Exxpharma, LLC (US) 2009-10-27 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
US-20080146581-A1 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety SANDOZ AG (CH) 2008-06-19 US claimed
EP-1915136-A2 COATED TABLES WITH ZERO-ORDER OR NEAR ZERO-ORDER RELEASE KINETICS Metrics, Inc. (US) 2008-04-30 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2007014061-A2 COATED TABLES WITH ZERO-ORDER OR NEAR ZERO-ORDER RELEASE KINETICS METRICS, INC. (US) 2007-02-01 WO claimed
US-20070020331-A1 Coated tablet with zero-order of near zero-order release kinetics CATALENT GREENVILLE, INC. 2007-01-25 US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20050249814-A1 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety SANDOZ AG (CH) 2005-11-10 US claimed
US-20050008704-A1 Pharmaceutical composition for solubility enhancement of hydrophobic drugs RAY ANUP KUMAR (US) 2005-01-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146581-A1 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety ABCG2, ABCB11, SLC10A1 ATM 4198/4885LMNA 4775/4885HTR2A 2410/4885
US-20050249814-A1 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety ABCG2, ABCB11, SLC10A1 ATM 4198/4885LMNA 4775/4885HTR2A 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.